PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MURA vs. IRON
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MURA and IRON is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

MURA vs. IRON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Mural Oncology plc (MURA) and Disc Medicine Inc. (IRON). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%SeptemberOctoberNovemberDecember2025February
29.21%
9.83%
MURA
IRON

Key characteristics

Sharpe Ratio

MURA:

-0.08

IRON:

-0.26

Sortino Ratio

MURA:

0.26

IRON:

0.17

Omega Ratio

MURA:

1.03

IRON:

1.03

Calmar Ratio

MURA:

-0.08

IRON:

-0.20

Martin Ratio

MURA:

-0.13

IRON:

-0.50

Ulcer Index

MURA:

33.66%

IRON:

37.15%

Daily Std Dev

MURA:

50.03%

IRON:

72.34%

Max Drawdown

MURA:

-50.58%

IRON:

-96.68%

Current Drawdown

MURA:

-28.62%

IRON:

-89.98%

Fundamentals

Market Cap

MURA:

$73.19M

IRON:

$1.86B

EPS

MURA:

-$9.09

IRON:

-$3.95

Total Revenue (TTM)

MURA:

$0.00

IRON:

$0.00

Gross Profit (TTM)

MURA:

-$1.75M

IRON:

-$136.00K

EBITDA (TTM)

MURA:

-$97.05M

IRON:

-$95.02M

Returns By Period

In the year-to-date period, MURA achieves a 33.23% return, which is significantly higher than IRON's -14.67% return.


MURA

YTD

33.23%

1M

7.25%

6M

29.22%

1Y

-12.98%

5Y*

N/A

10Y*

N/A

IRON

YTD

-14.67%

1M

-7.12%

6M

9.83%

1Y

-17.93%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MURA vs. IRON — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MURA
The Risk-Adjusted Performance Rank of MURA is 3939
Overall Rank
The Sharpe Ratio Rank of MURA is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of MURA is 3737
Sortino Ratio Rank
The Omega Ratio Rank of MURA is 3636
Omega Ratio Rank
The Calmar Ratio Rank of MURA is 3939
Calmar Ratio Rank
The Martin Ratio Rank of MURA is 4242
Martin Ratio Rank

IRON
The Risk-Adjusted Performance Rank of IRON is 3434
Overall Rank
The Sharpe Ratio Rank of IRON is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of IRON is 3535
Sortino Ratio Rank
The Omega Ratio Rank of IRON is 3636
Omega Ratio Rank
The Calmar Ratio Rank of IRON is 3333
Calmar Ratio Rank
The Martin Ratio Rank of IRON is 3535
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MURA vs. IRON - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Mural Oncology plc (MURA) and Disc Medicine Inc. (IRON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MURA, currently valued at -0.08, compared to the broader market-2.000.002.004.00-0.08-0.26
The chart of Sortino ratio for MURA, currently valued at 0.26, compared to the broader market-6.00-4.00-2.000.002.004.006.000.260.17
The chart of Omega ratio for MURA, currently valued at 1.03, compared to the broader market0.501.001.502.001.031.03
The chart of Calmar ratio for MURA, currently valued at -0.08, compared to the broader market0.002.004.006.00-0.08-0.29
The chart of Martin ratio for MURA, currently valued at -0.13, compared to the broader market-10.000.0010.0020.0030.00-0.13-0.50
MURA
IRON

The current MURA Sharpe Ratio is -0.08, which is higher than the IRON Sharpe Ratio of -0.26. The chart below compares the historical Sharpe Ratios of MURA and IRON, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19Jan 26Feb 02Feb 09
-0.08
-0.26
MURA
IRON

Dividends

MURA vs. IRON - Dividend Comparison

Neither MURA nor IRON has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MURA vs. IRON - Drawdown Comparison

The maximum MURA drawdown since its inception was -50.58%, smaller than the maximum IRON drawdown of -96.68%. Use the drawdown chart below to compare losses from any high point for MURA and IRON. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%SeptemberOctoberNovemberDecember2025February
-28.62%
-28.17%
MURA
IRON

Volatility

MURA vs. IRON - Volatility Comparison

Mural Oncology plc (MURA) has a higher volatility of 18.03% compared to Disc Medicine Inc. (IRON) at 8.94%. This indicates that MURA's price experiences larger fluctuations and is considered to be riskier than IRON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%SeptemberOctoberNovemberDecember2025February
18.03%
8.94%
MURA
IRON

Financials

MURA vs. IRON - Financials Comparison

This section allows you to compare key financial metrics between Mural Oncology plc and Disc Medicine Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab